Key result
Case report suggests PCSK9 inhibitors as potential lipid control therapy for hypertriglyceridemia-induced acute pancreatitis.
Why the study?
Familial hypercholesterolemia is underdiagnosed with less than 1% diagnosed, and prompt diagnosis and management of severe hypertriglyceridemia-induced acute pancreatitis are critical to reduce severity and mortality.
Case Report (n=1)
This case report highlights the importance of diagnosing and managing severe hypertriglyceridemia to prevent life-threatening complications like acute pancreatitis.
Answers are grounded in this paper and cite their sources.
May inform management of hypertriglyceridemia-induced pancreatitis; leaves open need for prospective validation.
The prevalence of familial hypercholesterolemia (FH) is about 1 in 200-500 in the general population, but approximately less than 1% of those affected are actually diagnosed. One of the most promising approaches to treat FH is utilizing human monoclonal antibodies. This is a case study describing a 47-year-old male patient who presented to the Emergency Department with acute abdominal pain caused by severe hypertriglyceridemia (HTG)-induced acute pancreatitis (AP). We report the steps necessary for establishing the right diagnosis and the management of HTG-induced AP, which are inevitable for the reduction of severity and mortality. This case study shows that hypercholesterolemia is an underdiagnosed and potentially lethal disease. Once diagnosed, all measures should be considered to control blood cholesterol and lipid levels. The decision to administer PCSK9 inhibitors should not be solely based on economical calculation, but rather individual factors should also be considered to weigh the risk/benefit ratio.
No takes yet. Share an insight, caveat, or question.
Molnár et al. (2021) conducted a case report in Severe hypertriglyceridemia-induced acute pancreatitis (n=1). Management of hypertriglyceridemia and PCSK9 inhibitors was evaluated. Management of severe hypertriglyceridemia-induced acute pancreatitis in a 47-year-old male highlights the need to control lipid levels, potentially utilizing PCSK9 inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: